## ORIGINAL

PTO/SB/64/PCT (12-04)

Approved for use through 03/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number

	DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER	(Optional) 5158N1P1			
	Named Inventor: Yamin WANG				
Ì	International (PCT) Application No.: PCT/US2004/011990	U.S. Application N (if known)	o.:		
	Filed: 16 April 2004 (16.04.2004)				
۱	itle: Hydroxamic Acids Useful in the Treatment of Hyper-Proliferative Disorders				
`					
	Attention: PCT Legal Staff Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450				
	The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.495(h).				
١	APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION				
	NOTE: A grantable petition requires the following items:  (1) Petition fee  (2) Proper reply  (3) Terminal disclaimer with disclaimer fee which is required for all international applications having an international filing date before June 8, 1995; and  (4) Statement that the entire delay was unintentional.				
	1. Petition fee Small entity - fee \$(37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.				
	Other than small entity - fee \$ 1,500.00 (37 CFR 1.17(m))				
	Proper reply     A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s)) in the form of				
l	The basic national fee (identify typ	e of reply):			
	has been filed previously on	·			
	is enclosed herewith.				
_	[Page 1 of 2]	10.1.10000			

[Page 1 of 2]
This collection of information is required by 37 CFR 1.137(b). The information is required to obtain of the confidence of information is required by 37 CFR 1.137(b). The information is required to obtain of the confidence of information is required by 35 U.S.C. 122 and 37 CFR 1.17 and 172 in the confidence of information is required by 35 U.S.C. 122 and 37 CFR 1.17 and 172 in the confidence of information of information is required by 35 U.S.C. 122 and 37 CFR 1.17 and 172 in the confidence of information of information is required by 35 U.S.C. 122 and 37 CFR 1.17 and 172 in the confidence of information of information of information of information of information of information of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

10/28/2005 LLANDGRA 00000033 133372 10554390

08 FC:1453

1500.00 DA

PTO/SB/64/PCT (12-04)
Approved for use through 03/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Since this international application has an interior is required.	rnational filing date on or after June 8, 1995, no terminal disclaime	
A terminal disclaimer (and disclaimer fee (37 \$ for other than a small entity) c (see PTO/SB/63).	CFR 1.20(d)) of \$ for a small entity or isclaiming the required period of time is enclosed herewith	
<ol> <li>Statement. The entire delay in filing the required filing of a grantable petition under 37 CFR 1.137(</li> </ol>	eply from the due date for the required reply until the b) was unintentional.	
	become public. Credit card information should not card information and authorization on PTO-2038.	
William F. Gray	20 October 2005	
Signature	Date	
William F. Gray	31,018	
Typed or Printed Name	Registration Number, if applicable	
Bayer Pharmaceuticals Corpo	ration (203) 812-2712	
Address	Telephone Number	
400 Morgan Lane, West Haven,	CT 06516	
Address		
Enclosures:  Response  The Commissioner is hereby authorized to charge Deposit Account No. 13 the amount of \$1,500.00 for the matters indicated above. The Commissioner also authorized to charge any additional fees, any underpayment of fees, and credit any overpayment to the above deposit account. A duplicate of this resistance.  Other (please identify):		
Transmittal Letter to the United     a Filing under 35 U.S.C. 371 [IN]	States Designated/Elected Office (DO/EO/US) Concerning DUPLICATE];	
2) Application Data Sheet under 3	' C.F.R. 1.76;	
3) Original executed oath or declar	ation of the inventor(s) (35 U.S.C. 371(c)(4));	
<ul><li>3) Original executed oath or declar</li><li>4) Copy of the International Applic</li></ul>		